Pneumologie Schlafmedizin und Onkologie am Diako Elke Dankelmann Bernhard Faderl Sabina Wehgartner-Winkler Michael Heller und Prof. Dr. med. Guenter Schlimok Partnerschaft

Research siteFast reply

Germany Froelichstrasse 17, Innenstadt, 86150 Augsburg, Germany

2 trials recruiting
Chronic obstructive pulmonary disease · Asthma
Adults and children

About Specializations

Pneumologie Schlafmedizin und Onkologie am Diako Elke Dankelmann Bernhard Faderl Sabina Wehgartner-Winkler Michael Heller und Prof. Dr. med. Guenter Schlimok Partnerschaft in Augsburg, Germany specialises in clinical trials of conditions such as Chronic obstructive pulmonary disease, Asthma, and other specialisations. This site conducts important research.

Main research areas of the site

Respiratory Tract Diseases

The center at the Zentrum für Pneumologie, Onkologie und Schlafmedizin am Diako conducts focused research on severe eosinophilic asthma, a challenging form of respiratory disease.

Evaluation of innovative anti‑eosinophilic treatments
Long‑term safety and tolerability assessment
Reduction of asthma exacerbation rates

Ongoing trials are designed to demonstrate the efficacy of a new therapy in lowering severe asthma attacks and enhancing patient wellbeing, reflecting the site’s commitment to advancing respiratory care.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Froelichstrasse 17, Innenstadt86150 AugsburgGermany

Open in maps ↗

Recruiting now: 2 trials
Conditions studied: 2

More sites in Augsburg Germany

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

9 clinical trials

Chronic obstructive pulmonary disease

Recruiting

Study on the Effects of Budesonide, Glycopyrronium, and Formoterol Fumarate for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Registered drugNo placebo

Study on the Effects of Budesonide, Glycopyrronium, and Formoterol Fumarate for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Budesonide
Sponsor:AstraZeneca AB

Contact Research Centre

Chronic obstructive pulmonary disease

Recruiting

Efficacy and safety of lunsekimig in adults with inadequately controlled eosinophilic COPD: a randomized, double‑blind, placebo‑controlled trial

Investigational

Efficacy and safety of lunsekimig in adults with inadequately controlled eosinophilic COPD: a randomized, double‑blind, placebo‑controlled trial

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Lunsekimig
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Chronic obstructive pulmonary disease

Not recruiting

Study of Verekitug to improve symptoms in patients with moderate to severe chronic obstructive pulmonary disease (COPD)

Investigational

Study of Verekitug to improve symptoms in patients with moderate to severe chronic obstructive pulmonary disease (COPD)

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Human IgG1 kappa monoclonal antibody against CRLF2
Sponsor:Upstream Bio Inc.

Contact Research Centre

Asthma

Not recruiting

Study of dupilumab added to inhaled corticosteroids and long-acting beta-agonists compared to high-dose inhaled therapy in adolescents and adults with uncontrolled asthma

Registered drug

Study of dupilumab added to inhaled corticosteroids and long-acting beta-agonists compared to high-dose inhaled therapy in adolescents and adults with uncontrolled asthma

Registered drug

Germany

Participants:0–17 years · 18–64 years · 65+ years
Substances:Dupilumab
Sponsor:Regeneron Pharmaceuticals Inc.

Contact Research Centre

Chronic obstructive pulmonary disease

Not recruiting

Study on the Effects of Astegolimab and Drug Combination for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Registered drug

Study on the Effects of Astegolimab and Drug Combination for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Registered drug

Germany

Participants:18–64 years · 65+ years
Sponsor:Genentech Inc.

Contact Research Centre

Chronic obstructive pulmonary disease

Not recruiting

Study of tozorakimab effectiveness and safety in former smokers with Chronic Obstructive Pulmonary Disease (COPD) who experience disease flare-ups

Registered drug

Study of tozorakimab effectiveness and safety in former smokers with Chronic Obstructive Pulmonary Disease (COPD) who experience disease flare-ups

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Salbutamol
Sponsor:AstraZeneca AB

Contact Research Centre

Asthma

Not recruiting

Study on the Effects of Dexpramipexole for Adolescents and Adults with Severe Eosinophilic Asthma

Registered drug

Study on the Effects of Dexpramipexole for Adolescents and Adults with Severe Eosinophilic Asthma

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Budesonide
Sponsor:Areteia Therapeutics Inc.

Contact Research Centre

Asthma

Not recruiting

Study on the Effectiveness and Safety of Fluticasone Propionate and Salbutamol Sulfate for Patients with Asthma

InvestigationalNo placebo

Study on the Effectiveness and Safety of Fluticasone Propionate and Salbutamol Sulfate for Patients with Asthma

InvestigationalNo placebo

Germany

Participants:0–17 years · 18–64 years · 65+ years
Substances:Salbutamol Sulfate
Sponsor:Teva Branded Pharmaceutical Products R&D LLC

Contact Research Centre

Asthma

Not recruiting

Study on Reducing Asthma Medication with Tezepelumab in Patients Aged 12 to 80 with Severe Asthma

Registered drugNo placebo

Study on Reducing Asthma Medication with Tezepelumab in Patients Aged 12 to 80 with Severe Asthma

Registered drugNo placebo

Germany

Participants:0–17 years · 18–64 years · 65+ years
Substances:Tezepelumab
Sponsor:AstraZeneca AB

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites